✦ LIBER ✦

Donepezil provides relevant therapeutic benefits in different domains to “real world” patients with Alzheimer's disease

✍ Scribed by F. Berger; C.-A. Sramko; L. Frölich; P. Calabrese

Book ID: 119574936
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 163 KB
Volume: 10
Category: Article
ISSN: 0924-977X
DOI: 10.1016/s0924-977x(00)80494-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PND10 COST-EFFECTIVENESS STUDY IN PATIEN

PND10 COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM

✍ D Getsios; S Blume; KJ Ishak; G MacLaine 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

Effects of donepezil 23 mg on Severe Imp

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer’s disease: evaluating the impact of baseline severity

✍ Ferris, Steven; Cummings, Jeffrey; Christensen, Daniel; Doody, Rachelle; Farlow, 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 286 KB

Cumulative Benefits of Extended-Release

Cumulative Benefits of Extended-Release Memantine (28 mg, Once Daily) Across Clinical Domains in Patients With Moderate to Severe Alzheimer's Disease: An Area Under the Curve Analysis

✍ Atri, Alireza; Tocco, Michael; Hendrix, Suzanne; Pejović, Vojislav; Graham, Step 📂 Article 📅 2014 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 64 KB

Extended-Release Memantine (28 mg, Once

Extended-Release Memantine (28 mg, Once Daily) Provides Behavioral Benefits Across a Wide Range of Disease Severity in Patients With Moderate to Severe Alzheimer's Disease: Post Hoc Analysis From a Randomized Trial

✍ Graham, Stephen M.; Hendrix, Suzanne; Miller, Michael L.; Pejović, Vojislav; Toc 📂 Article 📅 2013 🏛 American Psychiatric Publishing Inc 🌐 English ⚖ 49 KB